Idorsia Wins FDA Breakthrough Status for Pediatric Insomnia
Allschwil, Switzerland, November 4, 2026 Idorsia Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Allschwil, Switzerland, November 4, 2026 Idorsia Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted...
San Francisco, California, USA, November 3, 2026 Thryv Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative treatments...
New York, USA, November 3, 2026 Graviton BioScience Corporation has announced that the U.S. Food and Drug Administration (FDA)...
ARLINGTON, Massachusetts, U.S., October 29, 2026 Eloxx Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Dublin, Ireland — October 30, 2026 Alkermes plc announced the initiation of a Phase 2 clinical study evaluating ALKS...
Hong Kong, China, October 29, 2026 Ascletis Pharma Inc. has announced positive topline results from its U.S. Phase 2...
Newton, Massachusetts, US — October 30, 2026 Acumen Pharmaceuticals, Inc. announced that its Phase 2 ALTITUDE-AD clinical trial of...
Nantes, France — October 29, 2026 OSE Immunotherapeutics SA reported final positive results from its Combi-TED Phase 2 randomized...
South San Francisco, California — October 29, 2026 Assembly Biosciences, Inc. announced that the first two participants have been...
BOSTON, Massachusetts, United States — October 28, 2026 Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing molecular glue...
